Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin test skip for Kids' antibiotic allergies shows promise

NCT ID NCT03553251

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether children under 16 with a history of mild beta-lactam (like penicillin) allergies could safely take the drug again without first having skin tests. Researchers used a questionnaire to identify low-risk kids and then gave them an oral dose. The goal was to see if this approach kept severe allergic reactions below 2%. The study involved 195 children and aimed to simplify allergy care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-lactam antibiotics (e.g., penicillin)
What this could lead to
If successful, this could lead to simpler, faster allergy testing for children, avoiding unnecessary skin tests and allowing safe use of common antibiotics.
What could go wrong
This is a small, completed study with 195 children, so results may not apply to all kids. There is still a small risk of allergic reaction, and the approach only works for those already deemed low-risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

195 people

The number who actually took part.

Started

Sep 2018

Finished

Jul 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

children under 16 years of age with a clinical history that is not suggestive of IgE-mediated anaphylaxis or toxiderma to beta-lactams.

Ages

Up to 16 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children under 16 years of age coming for a consultation for a beta-lactam oral reintroduction test. Exclusion Criteria: * Refusal of the legal representatives of the subject for their child to participate in the study, * If his age permits, refusal of the subject to participate in the study, * Subject aged over 16, * Pregnancy, * Absence of affiliation of the subject to a social security scheme, * Skin tests with incriminated beta-lactam already made before the consultation, * Existence of contraindications to the realization of oral reintroduction drug test with the suspected antibiotic, * Existence of criteria in the initial reaction suggestive of a non-low risk of IgE-mediated or delayed hypersensitivity to the incriminated beta-lactam, Taking antihistamine, corticosteroids or beta-blockers within 5 days prior to the oral reintroduction drug test, * Travel abroad of the child scheduled within 7 days of the oral reintroduction drug test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Beta lactam adverse reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease drug allergy hypersensitivity reaction disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Beta lactam adverse reaction Hypersensitivity

Contacts and locations

Locations

  • Nantes University Hospital

    Nantes, Loire-Atlantique, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.